News
Post–COVID-19 lung injury: What we know so far
July 1, 2021
More than 30 million patients have been diagnosed with COVID-19 in the United States and close to half will experience persistent dyspnea.
News
Conservative treatment for spontaneous pneumothorax?
June 29, 2021
Is conservative management of moderate to large primary spontaneous pneumothorax an acceptable alternative to interventional treatment?
Opinion
Few clinical guidelines exist for treating post-COVID symptoms
June 24, 2021
‘We can prevent many infections from this virus, but we are still left to manage many post-COVID symptoms,’ says Dr. Linda Girgis.
News
Tofacitinib shows mortality benefit in patients with COVID-19 pneumonia
June 23, 2021
The Janus kinase inhibitor tofacitinib reduces the risk of both death and respiratory failure in hospitalized adults with COVID-19 pneumonia.
News
Prophylactic anticoagulation tied to lower death rate in COVID
June 18, 2021
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in Michigan.
News
U.S., international MIS-C studies yield disparate results
June 18, 2021
The two real-world observational studies were published online in The New England Journal of Medicine.
News
COVID-19 death toll higher for international medical graduates
June 11, 2021
These individuals are more likely to work in places where the incidence of COVID-19 is high and in facilities with fewer resources, according to the author of a new paper.
News
Collaborative effort reduces COPD readmissions, costs
June 6, 2021
A joint performance-improvement initiative helped reduce COPD-related ED visits and readmissions within 30 days of a COPD discharge.
News
High-flow nasal cannula improves dyspnea in palliative care patients with respiratory failure
June 2, 2021
Does a high-flow nasal cannula improve acute dyspnea in palliative care patients?
News
Avoiding excess oxygen in mechanically ventilated patients ‘seems sensible’
June 2, 2021
Future trials “will have to address how a particular [oxygenation] target is both set and achieved in each group of patients, particularly those with specific organ injuries.”